Surge In Cancer Cases Fuels Biologics Outsourcing Market Growth: A Key Factor Shaping the Future of the Biologics Outsourcing Market in 2025

How Are the key drivers contributing to the expansion of the biologics outsourcing market?
The escalating count of cancer incidents will likely fuel the expansion of the biologics outsourcing market in the future. Cancer represents a wide variety of diseases that can form in almost any organ or tissue when errant cells multiply excessively, exceed their normal limits, and either migrate to other organs or intrude on adjacent body parts. Biologics outsourcing is crucial in cancer instances, supplying specialized knowledge, resources, and equipment necessary for the creation, production, and clinical supply of biologic therapies, including monoclonal antibodies, immunotherapies, and other focused biologics used for detecting, treating, and managing diverse cancer types. For example, data from the National Center for Biotechnology Information, an intergovernmental organization in the United States, showed that in January 2023 there were 1,958,310 freshly diagnosed cancer cases in the United States, and by 2023, it was estimated that there will be 609,820 cancer deaths. Furthermore, it is estimated that the yearly count of new cancer cases is likely to increase to 29.5 million and cancer-related fatalities to 16.4 million by 2040. Thus, the escalating count of cancer incidents is stimulating the expansion of the biologics outsourcing market.

Get Your Biologics Outsourcing Market Report Here:
https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

What growth opportunities are expected to drive the biologics outsourcing market's CAGR through 2034?
In the last few years, there has been a notable increase in the size of the biologics outsourcing market. The market, which stood at $20.06 billion in 2024, is projected to reach $22.7 billion in 2025 with a compound annual growth rate (CAGR) of 13.2%. The historical growth of the market can be linked to factors such as rising R&D costs, regulatory constraints, the need for specific expertise, and globalization.

In the coming years, the biologics outsourcing market size is predicted to experience quick expansion. By 2029, its growth is expected to reach $37.52 billion, with a compound annual growth rate (CAGR) of 13.4%. The projected increase during this period is primarily due to factors such as the development of emerging markets, personalized medicine, strategic partnerships, and the expiry of biological drug patents. Key trends seen in this forecast period include technological advancements, a rise in outsourcing complexity, growth of the biosimilars market, incorporation of data analytics, and resilience in the supply chain.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12573&type=smp

What are the emerging trends shaping the future of the biologics outsourcing market?
Advancements in the field of biologics are gaining traction and becoming a significant trend in the biologics outsourcing market. To stay competitive in this market, major companies are incorporating new technologies. For example, in February 2022, Alira Health, Abzena, and Oncodesign, which are prominent healthcare, CDMO, and biopharmaceutical companies respectively, initiated DRIVE-Biologics, a collaborative effort intended for the discovery and development of biologic drugs. This initiative furnishes integrated solutions accompanied by specialist services, ranging from biological discovery to commercial manufacturing and clinical. By combining their expertise in areas like design and developability, preclinical pharmacology and pharmaco-imaging, toxicology, and commercial manufacturing, they aim to facilitate information exchange and deliverables to efficaciously mitigate the risk in biologics development. Moreover, collaboration partners can tap into expertise throughout all stages of drug discovery and development, including design, preclinical, clinical, and CMC (chemistry, manufacturing, and control).

Which growth-oriented segments of the biologics outsourcing market are leading the industry's development?
The biologics outsourcing market covered in this report is segmented -

1) By Product Type: Antibodies, Recombinant, Vaccines, Protein, Other Products
2) By Source: Human, Microbial, Other Source
3) By Application: Oncology, Cellular And Gene Therapy, Blood And Blood-Related Products Development, Vaccine Development, Stem Cell Research, Other Applications
4) By End User: Pharmaceutical Industries, Biotechnology Industries, Contract Development And Manufacturing Organization(CDMO)

Subsegments:
1) By Antibodies: Monoclonal Antibodies, Polyclonal Antibodies
2) By Recombinant: Recombinant Proteins, Recombinant DNA Products
3) By Vaccines: Therapeutic Vaccines, Preventive Vaccines
4) By Protein: Enzymes, Hormones, Cytokines
5) By Other Products: Gene Therapies, Cell Therapies, Biosimilars

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12573

What regions are leading the charge in the biologics outsourcing market?
North America was the largest region in the biologics outsourcing market in 2024. The regions covered in the biologics outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What companies are at the forefront of innovation in the biologics outsourcing market?
Major companies operating in the biologics outsourcing market include AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12573&type=smp

What Is Covered In The Biologics Outsourcing Global Market Report?

• Market Size Forecast: Examine the biologics outsourcing market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the biologics outsourcing market for a structured understanding.
• Key Players Overview: Analyze major players in the biologics outsourcing market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the biologics outsourcing market.
• Segment Contributions: Evaluate how different segments drive overall growth in the biologics outsourcing market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the biologics outsourcing market.
• Industry Challenges: Identify potential risks and obstacles affecting the biologics outsourcing market.
• Competitive Landscape: Review strategic developments in the biologics outsourcing market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.